In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

VC View: Deal-Making During A Pandemic And 2021 Expectations

Interview With Naseem Amin And Christian Schetter

Executive Summary

In the latest instalment of VC Playbook, In Vivo gets to know Arix Bioscience, a relatively young venture capital firm that went public in 2016. Arix has “has many similarities yet some key differences from a typical venture capital firm,” says the management team.

You may also be interested in...



Iterum Anxiously Awaiting Other Results After SURE 3 Failure

Iterum’s antibiotic sulopenem missed its endpoint by the equivalent of one patient. The company believes the Phase III data could still support its NDA for urinary tract infections.

VelosBio CEO: Series A Success Shows Investors Back His ADC Formula

VelosBio's well-backed Series A funding round showed that investors believe his team has identified the right combination of cancer target, linker and payload for creating a successful novel ADC, the biotech's CEO told Scrip.

Assessing Artios: $83m Series B, Big-Name Investors, Nothing In The Clinic

Cambridge, UK-based Artios Pharma attracted several new investors for its over-subscribed series B round in August 2018, but the company is yet to enter the clinic with its DNA repair drug portfolio and has many hurdles ahead to validate its technology. Scrip speaks to investors from LSP and Arix about why preclinical-stage biotechs are getting more attention in 2018.

Topics

Related Companies

UsernamePublicRestriction

Register

ID034708

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel